ReNeuron Group (LON:RENE) Trading Down 2%

Shares of ReNeuron Group Plc (LON:RENE) dropped 2% on Thursday . The stock traded as low as GBX 120 ($1.57) and last traded at GBX 124 ($1.62), approximately 9,752 shares were traded during mid-day trading. A decline of 66% from the average daily volume of 28,700 shares. The stock had previously closed at GBX 126.50 ($1.65).

The company has a market capitalization of $39.00 million and a P/E ratio of -2.71. The firm has a 50 day moving average price of GBX 159.46 and a two-hundred day moving average price of GBX 222.55.

About ReNeuron Group (LON:RENE)

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.

Featured Story: What is a Swap?

Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.